SuperworthMerck EPS MRK
Diluted earnings per share by quarter and over the last twelve months, from 2008.
- Last 12 months, to Jun 30, 2026
- $1.25
- Latest quarter, Q2 FY26
- −$0.54
- −131% on a year earlier
- Fiscal year 2025
- $7.28
- +8% on the year before
Merck's earnings per share was $1.25 over the twelve months to Jun 30, 2026, down 81% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.54, down 131% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 21% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $7.28 | +8% |
| FY2024 | $6.73 | +4707% |
| FY2023 | $0.14 | −98% |
| FY2022 | $5.71 | +11% |
| FY2021 | $5.14 | +86% |
| FY2020 | $2.77 | −27% |
| FY2019 | $3.81 | +64% |
| FY2018 | $2.32 | +170% |
| FY2017 | $0.86 | −38% |
| FY2016 | $1.39 | −11% |
| FY2015 | $1.56 | −62% |
| FY2014 | $4.10 | +181% |
| FY2013 | $1.46 | −27% |
| FY2012 | $2.00 | −1% |
| FY2011 | $2.03 | +652% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.54 | −131% | $1.25 | |
| Q1 FY26 | −$1.72 | −186% | $3.55 | |
| Q4 FY25 | $1.19 | −20% | $7.28 | |
| Q3 FY25 | $2.32 | +87% | $7.57 | |
| Q2 FY25 | $1.76 | −18% | $6.49 | |
| Q1 FY25 | $2.01 | +7% | $6.87 | |
| Q4 FY24 | $1.48 | n/a | $6.73 | |
| Q3 FY24 | $1.24 | −33% | $4.77 | |
| Q2 FY24 | $2.14 | n/a | $5.39 | |
| Q1 FY24 | $1.87 | +68% | $0.90 | |
| Q4 FY23 | −$0.48 | −141% | $0.14 | |
| Q3 FY23 | $1.86 | +45% | $1.80 |
Against its peers
Companies in Drug Manufacturers - General nearest Merck's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MRKMerck | $1.25 | −81% a year |
| ABBVAbbVie | $3.54 | +69% a year |
| AMGNAmgen | $16.09 | +32% a year |
| JNJJohnson & Johnson | $6.60 | −36% a year |
| GILDGilead Sciences | −$2.67 | −153% a year |
| PFEPfizer | $0.76 | −60% a year |
| BMYBristol-Myers Squibb | $4.54 | +83% a year |
| LLYEli Lilly and | $29.80 | +95% a year |
| BIIBBiogen | $5.65 | −46% a year |
| Peer median | $5.09 |
Where Merck ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Merck
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.